Welcome! Log into your account
Forgot your password? Get help
Recover your password
A password will be e-mailed to you.
Tag: Samsung Bioepis
Biogen expands its ownership in Samsung Bioepis
Biogen announced it has exercised its option to purchase additional shares of Samsung Bioepis Co., Ltd., a joint venture established in 2012 by Samsung BioLogics and Biogen.
AbbVie reached a resolution in intellectual property-related dispute
AbbVie announced it reached a global resolution for all intellectual property-related litigation with the two companies regarding its biosimilar Imraldi (adalimumab).
Samsung Bioepis biosimilar cancer drug begun to sell in Europe
Korean biopharmaceutical firm Samsung Bioepis informed that its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator (EMA).
Samsung Bioepis received EU approval for its Herceptin biosimilar
Samsung Bioepis announced the European Commission’s marketing authorization of ONTRUZANT, a biosimilar referencing Herceptin (trastuzumab)
Samsung Bioepis and Takeda will jointly develop new drugs
Samsung Bioepis Co., Ltd. announced that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company
Rafarma – a full cycle pharmaceutical enterprise
Binnopharm – full-cycle biopharmaceutical faciliti...
Pharmacor Production Ltd.
V.P. Filatov Pharmaceutical Plant
R-Pharm – Russian High-Tech Pharmaceutical Enterprise
PIQ-PHARMA Group of Companies
GMP Inspection practice: a case for global benchmarking, con...
Merck KGaA will lead Global Oncology Big Data Alliance
Conference GEP-Russia 2017: Sterile Forms and Biotechnology
MIPT delivers world’s first biosensor chips of unprecedented...
German CDMO HERMES PHARMA receives Russian GMP certification...
Amgen will transfer technology for manufacturing of blinatum...
Subscribe to Newsletter!
© GMP news